Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616693 | 0.81 | MDM2 (0.61) | MDM2KDM4EL3MBTL1POLBTAAR1 | |
| SCHEMBL514783 | 0.78 | SMN1; SMN2 (0.56) | KMT2AMEN1GAAEPHX1LMNA | |
| SCHEMBL9089988 | 0.77 | MAPT (0.54) | KDM4EL3MBTL1POLBKMT2AMEN1 | |
| SCHEMBL5417314 | 0.76 | MDM2 (0.67) | MDM2KDM4EL3MBTL1TAAR1BCHE | |
| SCHEMBL2095089 | 0.75 | ALDH1A1 (0.55) | KDM4EPOLBTAAR1KMT2AMEN1 | |
| SCHEMBL515017 | 0.75 | MAPT (0.59) | KDM4EPOLBKMT2AMEN1GAA | |
| SCHEMBL514570 | 0.75 | TDP1 (0.57) | KDM4EPOLBLMNA | |
| SCHEMBL2094114 | 0.75 | NPC1 (0.55) | L3MBTL1KMT2AMEN1GAAEPHX1 | |
| SCHEMBL514280 | 0.75 | CA12 (0.45) | EPHX1 | |
| SCHEMBL10020286 | 0.75 | MDM2 (1.00) | MDM2KDM4EL3MBTL1POLBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190296-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | US | disclosed |
| US-20110190369-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | US | disclosed |
| EP-2319843-A1 | Substituted pyrrole derivatives and their use as HMG-CO inhibitors | Ranbaxy Laboratories Limited (IN) | 2011-05-11 | — | — | EP | disclosed |
| US-7923467-B2 | Substituted pyrrole derivatives and their use as HMG-CO inhibitors | Ranbaxy Laboratories, Inc. (IN) | 2011-04-12 | — | — | US | disclosed |
| US-20100056602-A1 | Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056602-A1 | Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors | HMGCR, HMGB2, HMGB3 | MDM2 3363/4885KDM4E 870/4885L3MBTL1 4214/4885 |
| US-20110190369-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | HMGCR, HMGB2, HMGB3 | MDM2 3363/4885KDM4E 870/4885L3MBTL1 4214/4885 |
| US-20110190296-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | HMGCR, HMGB2, HMGB3 | MDM2 3363/4885KDM4E 870/4885L3MBTL1 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.